| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2020NatCo..11.6024C |
| P356 | DOI | 10.1038/S41467-020-19543-W |
| P698 | PubMed publication ID | 33247134 |
| P50 | author | Lei Liu | Q84592844 |
| Hyun-Sik Yang | Q87912511 | ||
| Jasmeer Chhatwal | Q90246725 | ||
| P2093 | author name string | Dennis J Selkoe | |
| Keith A Johnson | |||
| Reisa A Sperling | |||
| Aaron P Schultz | |||
| Yifan Dang | |||
| Beth Ostaszewski | |||
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| “Mini-mental state” | Q25938989 | ||
| Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography | Q28273817 | ||
| General cardiovascular risk profile for use in primary care: the Framingham Heart Study | Q29614189 | ||
| A general framework for formal tests of interaction after exhaustive search methods with applications to MDR and MDR-PDT. | Q33534676 | ||
| The preclinical Alzheimer cognitive composite: measuring amyloid-related decline | Q34422469 | ||
| The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults | Q92113474 | ||
| Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease | Q92403034 | ||
| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts | Q93222023 | ||
| Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders | Q98156874 | ||
| Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease | Q34493453 | ||
| Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. | Q34940642 | ||
| Within-subject template estimation for unbiased longitudinal image analysis | Q36075413 | ||
| CSF neurofilament proteins in the differential diagnosis of dementia | Q36227579 | ||
| Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community | Q36456068 | ||
| Tau positron emission tomographic imaging in aging and early Alzheimer disease | Q36535275 | ||
| Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. | Q38378624 | ||
| Probing Interactions in Fixed and Multilevel Regression: Inferential and Graphical Techniques | Q38705796 | ||
| C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death. | Q38847942 | ||
| Memory impairment on free and cued selective reminding predicts dementia | Q40776738 | ||
| Harvard Aging Brain Study: Dataset and accessibility | Q41114609 | ||
| Socioeconomic status, ethnicity, and risk of coronary heart disease | Q43412628 | ||
| Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease | Q43593305 | ||
| Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity | Q46045880 | ||
| Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. | Q47141681 | ||
| Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases | Q48682038 | ||
| Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. | Q49015259 | ||
| High performance plasma amyloid-β biomarkers for Alzheimer's disease | Q50107488 | ||
| NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Q52589491 | ||
| Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. | Q53388052 | ||
| Alzheimer disease: Neurofilament light in the blood marks Alzheimer degeneration. | Q53503513 | ||
| The Johnson-Neyman technique, its theory and application. | Q54539259 | ||
| Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease | Q59811717 | ||
| Current state of Alzheimer's fluid biomarkers | Q60310921 | ||
| Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease | Q60961744 | ||
| Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis | Q64761571 | ||
| Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. | Q64996689 | ||
| Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography | Q88296166 | ||
| Tau Kinetics in Neurons and the Human Central Nervous System | Q88716750 | ||
| Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study | Q88813117 | ||
| Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis | Q88960884 | ||
| Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia | Q89984102 | ||
| Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration | Q89984108 | ||
| Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults | Q90078937 | ||
| Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease | Q90139959 | ||
| Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer's Disease: A Correlative Meta-Analysis | Q90399865 | ||
| Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease | Q90588474 | ||
| Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study | Q90613879 | ||
| Vascular Risk and β-Amyloid Are Synergistically Associated with Cortical Tau | Q90628286 | ||
| Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study | Q90698412 | ||
| Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease | Q91222301 | ||
| Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD | Q91413917 | ||
| Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis | Q91544043 | ||
| Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease | Q91555490 | ||
| Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults | Q91944245 | ||
| Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes | Q92103818 | ||
| P433 | issue | 1 | |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 6024 | |
| P577 | publication date | 2020-11-27 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals | |
| P478 | volume | 11 |
Search more.